SPOTLIGHT -
In August 2022, the FDA granted approval to oral darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer.
E. David Crawford, MD, Reviews the Evolution of Treatment for mHSPC Leading to the FDA Approval of Darolutamide, Chemo, and ADT
In light of the recent FDA approval of darolutamide plus docetaxel and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer, E. David Crawford, MD, discussed the research that paved the way for the regulatory decision and where future efforts need to be focused.
FDA Approves Oral Darolutamide/Docetaxel for Metastatic HSPC
Patients with metastatic hormone-sensitive prostate cancer can now receive treatment with oral darolutamide plus docetaxel following its approval by the FDA.
E. David Crawford, MD, Reviews Unmet Needs Addressed by FDA Approval of Darolutamide, Docetaxel, and ADT in mHSPC
In an interview with CancerNetwork®, E. David Crawford, MD, discussed implications from the recent FDA approval of darolutamide plus docetaxel and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer based on findings from the phase 3 ARASENS trial.